- Home
- JXG vs GNLX Comparison
JXG vs GNLX Comparison
Compare JXG & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JXG | GNLX |
|---|---|---|
| Founded | N/A | 2001 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.6M | 110.4M |
| IPO Year | 2012 | 2022 |
Fundamental Metrics
Financial Performance| Metric | JXG | GNLX |
|---|---|---|
| Price | $7.20 | $2.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.83 |
| AVG Volume (30 Days) | 33.3K | ★ 421.9K |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $1.86 |
| 52 Week High | $12.00 | $8.54 |
Technical Indicators
Market Signals| Indicator | JXG | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 48.36 | 37.48 |
| Support Level | $6.11 | N/A |
| Resistance Level | $7.97 | $2.78 |
| Average True Range (ATR) | 0.71 | 0.23 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 54.49 | 18.61 |
Price Performance
Historical ComparisonAbout JXG JX Luxventure Limited
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products. The Company's operations are located in the PRC and all of the Company's revenue is derived from sales to customers in the PRC region.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.